Press

Over 30 innovative biotech companies possess the comprehensive capabilities to develop advanced therapies, from initial R&D through manufacturing, efficient transfer and distribution

• AseBio gave an advance look at these figures at an event celebrating the 20th anniversary of BIOSPAIN, two decades over which a total of €1.2 billion has been invested in the biotechnology sector

•  The presentation took place at the Meta Space in Madrid with Secretary General for Innovation Teresa Riesgo and AseBio Chairwoman Ana Polanco
• The analysis highlights that 60% of all people who work at companies in the sector are women and that 98% of them have been to university.
•  At 37% of the companies, more than 50% of leadership positions are held by women, according to the document.

• The forum is held in Malaga with over 3,000 professionals from the science and innovation sector. AseBio is displaying innovative bioproducts from over a dozen member companies that are tackling the green transition, as well as hosting a panel discussion to highlight the work being done in the biotechnology industry to drive cutting-edge healthcare and reinforce the National Health System 

• For International Day of Women and Girls in Science, 14 women from 12 companies will host young female students to encourage them to go into science and innovation and show them the different professional careers available in the biotech industry

• BIOSPAIN 2023 expects to bring together over 1,500 professionals from 30 countries around the world in Barcelona, opening up business opportunities with more than 2,000 one-to-one meetings and 50 investors from Spain and abroad.
• Barcelona, the leader in the biotechnology and life sciences sector in Spain, will host this edition from 26 to 28 September, which is the 20th anniversary of the event.
• During the presentation, AseBio, Biocat, the Government of Catalonia and the Barcelona City Council highlighted the urgent need for a greater commitment to the science and innovation generated by biotechnology companies as a way to tackle the challenges of the future, such as antimicrobial resistance, the ageing population and climate change.

• 86.6% of studies under way focus on improving people’s health and nearly 14% on protecting the planet. Of all these innovations, 203 are already available on the market or ready for exploitation
• Of all these innovations, a total of 203 are ready for exploitation or available on the market.
• However, 88% of the national companies' biomedicine research pipelines are still in the early stages. 

• AseBio and FUNDECYT-PCTEx are holding the fifth edition of the Green Innovation Forum in Mérida, Extremadura.
• More than 300 experts from the Spanish biotechnology sector have gathered to promote a new model of economic growth marked by the green transition. 

• AseBio and ASD present in Madrid the document with the main conclusions on the state of new technologies in the industry. 
• One of the proposals for action is to train professionals and develop a strategy for their implementation and permanence over time.